TY - JOUR
T1 - Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men
AU - New York Acute Hepatitis C Surveillance Network
AU - Palaniswami, Paari M.
AU - Sayed, Ahmed El
AU - Asriel, Benjamin
AU - Carollo, Jesse R.
AU - Fierer, Daniel S.
AU - Akil, Bisher
AU - Bailey, Juan
AU - Bellman, Paul
AU - Bowers, Daniel
AU - Bungay, Krisczar
AU - Burger, Susanne
AU - Cantor, Aviva
AU - Chasan, Rachel
AU - Chavez, Robert
AU - Chow, Rita
AU - Cohen, Robert
AU - Dalton, Patrick
AU - Dellosso, John
AU - Dillon, Stephen
AU - Donlon, Eileen
AU - Farrow, Terry
AU - Fefer, Jose
AU - Gaisa, Michael
AU - Guadron, Rodolfo
AU - Haber, Stuart
AU - Hefron, Susan
AU - Higgins, Lawrence
AU - Hitzeman, Lawrence
AU - Hsu, Ricky
AU - Huprikar, Shirish
AU - Inada, Victor
AU - Jacob, Sneha
AU - Johnson, Livette
AU - Johnston, Barbara
AU - Kaminsky, Donald
AU - Klein, Oscar
AU - Kwong, Jeffrey
AU - Lares-Guia, Jose
AU - Leach, Eric
AU - Levine, Randy
AU - Linetskaya, Irina
AU - Litvinova, Larisa
AU - Malhotra, Amisha
AU - Mandell, William
AU - Markowitz, Martin
AU - Mayer, Gal
AU - Meraz, Eddie
AU - Mortensen, Erik
AU - Olivieri, Joseph
AU - Rapaport, Steven
N1 - Funding Information:
Potential conflicts of interest. D.S.F. reports being on the steering committee for, a speaker for, and receiving honoraria from the Chronic Liver Disease Foundation; having been a speaker for and received honoraria from the National Committee for Quality Assurance; and having received research funding from and owning common stock in Gilead Sciences, Inc. No other authors report any conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Publisher Copyright:
© The Author(s) 2018.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Background. Treatment of HIV-infected men during early hepatitis C virus (HCV) infection with interferon results in a higher cure rate with a shorter duration of treatment than during chronic HCV infection. We recently demonstrated that this phenomenon applied to interferon-free treatment as well, curing most participants with short-course sofosbuvir and ribavirin. Due to the significantly higher potency of the ledipasvir/sofosbuvir (LDV/SOF) combination, we hypothesized that we would be more successful in curing early HCV infections using a shorter course of LDV/SOF than that used for treating chronic HCV infections. Methods. We performed a prospective, open-label, consecutive case series study of 8 weeks of LDV/SOF in HIV-infected men with early genotype 1 HCV infection. The primary end point was aviremia at least 12 weeks after completion of treatment. Results. We treated 25 HIV-infected men with early sexually acquired HCV infection with 8 weeks of LDV/SOF, and all 25 (100%) were cured. Twelve (48%) reported sexualized drug use with methamphetamine. Conclusions. Eight weeks of LDV/SOF cured all 25 HIV-infected men with early HCV infection, including those who were actively using drugs. Based on these results, we recommend treatment of newly HCV-infected men during early infection, regardless of drug use, to both take advantage of this 8-week treatment and to decrease further HCV transmission among this group of men.
AB - Background. Treatment of HIV-infected men during early hepatitis C virus (HCV) infection with interferon results in a higher cure rate with a shorter duration of treatment than during chronic HCV infection. We recently demonstrated that this phenomenon applied to interferon-free treatment as well, curing most participants with short-course sofosbuvir and ribavirin. Due to the significantly higher potency of the ledipasvir/sofosbuvir (LDV/SOF) combination, we hypothesized that we would be more successful in curing early HCV infections using a shorter course of LDV/SOF than that used for treating chronic HCV infections. Methods. We performed a prospective, open-label, consecutive case series study of 8 weeks of LDV/SOF in HIV-infected men with early genotype 1 HCV infection. The primary end point was aviremia at least 12 weeks after completion of treatment. Results. We treated 25 HIV-infected men with early sexually acquired HCV infection with 8 weeks of LDV/SOF, and all 25 (100%) were cured. Twelve (48%) reported sexualized drug use with methamphetamine. Conclusions. Eight weeks of LDV/SOF cured all 25 HIV-infected men with early HCV infection, including those who were actively using drugs. Based on these results, we recommend treatment of newly HCV-infected men during early infection, regardless of drug use, to both take advantage of this 8-week treatment and to decrease further HCV transmission among this group of men.
KW - Acute HCV
KW - Enhanced treatment responsiveness
KW - HIV-infected men who have sex with men (MSM)
KW - Sexualized methamphetamine drug use
UR - http://www.scopus.com/inward/record.url?scp=85068036430&partnerID=8YFLogxK
U2 - 10.1093/ofid/ofy238
DO - 10.1093/ofid/ofy238
M3 - Article
AN - SCOPUS:85068036430
SN - 2328-8957
VL - 5
JO - Open Forum Infectious Diseases
JF - Open Forum Infectious Diseases
IS - 10
ER -